Effects of Tibetan medicine Longdan zhike tablet on chronic obstructive pulmonary disease through MAPK pathway.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE:

Longdan zhike tablet (LDZK) is a Tibetan medicine formula commonly used in the highland region of Tibet, China, to ameliorate respiratory diseases, such as acute bronchitis and asthma. In Chinese traditional medicine, some herbal formulas with anti-inflammatory properties targeting the respiratory system are clinically adopted as supplementary therapies for chronic obstructive pulmonary disease (COPD). However, the specific anti-COPD effects of LDZK remain to be evaluated.

AIM OF THE STUDY:

The aim of this study is to identify the principal bioactive compounds in LDZK, and elucidate the effects and mechanisms of the LDZK on COPD.

METHODS:

High-resolution mass spectrometry was utilized for a comprehensive characterization of the chemical composition of LDZK. The therapeutic effects of LDZK were assessed on the LPS-papain-induced COPD mouse model, and LPS-induced activation model of A549 cells. The safety of LDZK was evaluated by orally administering a single dose of 30 g/kg to rats and monitoring physiological and biochemical indicators after a 14-day period. Network pharmacology and Western blot analysis were employed for mechanism prediction of LDZK.

RESULTS:

A comprehensive analysis identified a total of 45 compounds as the major constituents of LDZK. Oral administration of LDZK resulted in notable ameliorative effects in respiratory function, accompanied by reduced inflammatory cell counts and cytokine levels in the lungs of COPD mice. Acute toxicity tests demonstrated a favorable safety profile at a dose equivalent to 292 times the clinically prescribed dose. In vitro studies revealed that LDZK exhibited protective effects on A549 cells by mitigating LPS-induced cellular damage, reducing the release of NO, and downregulating the expression of iNOS, COX2, IL-1β, IL-6, and TNF-α. Network pharmacology and Western blot analysis indicated that LDZK primarily modulated the MAPK signaling pathway and inhibited the phosphorylation of p38/ERK/JNK.

CONCLUSIONS:

LDZK exerts significant therapeutic effects on COPD through the regulation of the MAPK pathway, suggesting its potential as a promising adjunctive therapy for the treatment of chronic inflammation in COPD.

• Authors: Yulin Feng, Pengfei Qin, Rong Wang, Yahui Mi, You Li, Jiahao Feng, Wenbin Shen, Haijuan Dong, Jietai Duo, Liming Ma, Xiaowu Yao, Xiaolong Hu, Fei Xiong, Xinhong Shi, Hao Wang
• Journal: Journal of ethnopharmacology (J Ethnopharmacol) Vol. 328 Pg. 118082 (Jun 28 2024) ISSN: 1872-7573 [Electronic] Ireland
• PMID: 38522625 (Publication Type: Journal Article)
• Copyright: Copyright © 2024 Elsevier B.V. All rights reserved.

Chemical References

• Lipopolysaccharides

Topics

• Rats
• Mice
• Animals
• Medicine, Tibetan Traditional
• Lipopolysaccharides (pharmacology)
• Pulmonary Disease, Chronic Obstructive (drug therapy, metabolism)
• Lung
• Signal Transduction